Last reviewed · How we verify
LY2928057
At a glance
| Generic name | LY2928057 |
|---|---|
| Also known as | Ferroportin antibody |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of LY2928057 in Hemodialysis Participants (PHASE1)
- A First Human Study of a Ferroportin Antibody (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY2928057 CI brief — competitive landscape report
- LY2928057 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI